Oct 21, 2021
The lack of behavioral interventions that aim to increase physical activity (PA) among individuals with fatigue prompted researchers to examine variables of social cognitive theory (SCT) as correlates of PA among adult patients...
Read MoreOct 21, 2021
Research demonstrates that Black Americans with MS experience more aggressive disease and a higher lesion burden when compared with White Americans, but the factors associated with these disparities have not been examined. To...
Read MoreOct 21, 2021
While COVID-19 vaccines are recommended for people with neuromyelitis optica spectrum disorder (NMOSD) and MOG-antibody-associated disease (MOGAD), they were not specifically tested in this population, and thus, have an unclear...
Read MoreOct 21, 2021
Investigators reported final safety and efficacy data from the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), in which patients aged 18 and older who had an Expanded Disability Status Scale...
Read MoreOct 21, 2021
Previous studies have examined the platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios as biomarkers of inflammation and disease activity in autoimmune diseases. Researchers assessed the ability of these...
Read MoreOct 21, 2021
Using a propensity score-matching methodology, investigators examined the economic and healthcare burden of neuromyelitis optica spectrum disorder (NMOSD). The study team performed a retrospective analysis of two claims datasets...
Read MoreOct 21, 2021
Researchers sought to determine how well brain and spinal cord lesion criteria perform in discerning MS from neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease...
Read MoreOct 19, 2021
Less flushing also seen, compared to dimethyl fumarate Flushing and gastrointestinal (GI) distress are common side effects of oral fumarates used to treat patients with multiple sclerosis, but the frequency of these events was...
Read MoreOct 19, 2021
MS relapse rate lower with natalizumab than ocrelizumab in real-world analysis Infusions of the disease-modifying therapy natalizumab—given every 6 weeks instead of the approved 4-week dosing schedule—proved to be...
Read MoreOct 18, 2021
MS relapse rate lower with natalizumab than ocrelizumab in real-world analysis Infusions of the disease-modifying therapy natalizumab—given every 6 weeks instead of the approved 4-week dosing schedule—proved to be...
Read MoreOct 15, 2021
Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity Results from a new analysis of the inebilizumab pivotal Phase 2/3 N-MOmentum trial were presented this year...
Read MoreOct 12, 2021
Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....
Read MoreOct 12, 2021
There are geographic disparities in access to clinical trial sites for neovascular age-related macular degeneration (nAMD) in the US. While proximity to urban centers is beneficial for efficiency and retention of subjects, the...
Read MoreOct 12, 2021
Analysis suggests that daily self-imaging generated images of satisfactory quality for human grading and automated analysis of fluid volume over time permitting a novel paradigm of monitoring. Home OCT may allow personalized...
Read MoreOct 12, 2021
The average patient with neovascular age-related macular degeneration (nvAMD) would not qualify for the trials that determine current standards of care. Clinical trial methodology could be to blame for real-world patients having...
Read MoreOct 11, 2021
Data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) will be highlighted at the upcoming 37th Congress of the European Committee for Treatment and...
Read MoreOct 11, 2021
A total of 10 Janssen-sponsored data abstracts on MS research will be presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress from October 13 to 15, in Vienna,...
Read MoreOct 11, 2021
Check Out the New Interactive Program ePoster Tours This year’s ECTRIMS we will have 8 poster tours that will highlight the top scored ePoster. All top scored ePoster authors have been contacted. Poster Tour 1 – Clinical:...
Read MoreOct 11, 2021
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Vienna is the world’s largest annual international conference devoted to basic and clinical research in multiple...
Read MoreOct 11, 2021
New data on inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) will be presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021, Oct. 13-15....
Read More
